Somewhat Positive Media Coverage Somewhat Unlikely to Affect Nektar Therapeutics (NKTR) Share Price

News articles about Nektar Therapeutics (NASDAQ:NKTR) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nektar Therapeutics earned a news impact score of 0.25 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.2261803763772 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up $4.03 on Monday, reaching $107.03. 2,417,846 shares of the company traded hands, compared to its average volume of 3,278,878. The company has a market capitalization of $16,575.06, a price-to-earnings ratio of -164.66 and a beta of 1.96. The company has a debt-to-equity ratio of 2.79, a quick ratio of 5.63 and a current ratio of 5.82. Nektar Therapeutics has a 52-week low of $17.33 and a 52-week high of $111.36.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.14. The firm had revenue of $95.47 million for the quarter, compared to analyst estimates of $36.96 million. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The company’s revenue for the quarter was up 154.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.28) earnings per share. research analysts expect that Nektar Therapeutics will post -1.33 EPS for the current year.

NKTR has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Canaccord Genuity reissued a “buy” rating and issued a $80.00 price target (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Jefferies Group increased their price target on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Mizuho increased their price target on shares of Nektar Therapeutics from $45.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, January 22nd. Finally, BidaskClub lowered shares of Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 8th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $54.75.

In other news, Director Christopher A. Kuebler sold 30,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total value of $1,759,800.00. Following the sale, the director now owns 70,500 shares in the company, valued at $4,135,530. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Stephen K. Doberstein sold 2,426 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $82.94, for a total transaction of $201,212.44. Following the completion of the sale, the senior vice president now owns 67,394 shares in the company, valued at approximately $5,589,658.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 399,592 shares of company stock worth $36,001,781. 5.44% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Nektar Therapeutics (NKTR) Share Price” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3303174/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-nektar-therapeutics-nktr-share-price.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Marten Transport, Ltd.  Expected to Earn Q3 2018 Earnings of $0.24 Per Share
Marten Transport, Ltd. Expected to Earn Q3 2018 Earnings of $0.24 Per Share
Senseonics Holdings  Sees Large Growth in Short Interest
Senseonics Holdings Sees Large Growth in Short Interest
Short Interest in Uranium Energy  Declines By 0.4%
Short Interest in Uranium Energy Declines By 0.4%
Allegheny Technologies  Shares Up 0% on Strong Earnings
Allegheny Technologies Shares Up 0% on Strong Earnings
Traders Sell NextEra Energy  on Strength on Disappointing Earnings
Traders Sell NextEra Energy on Strength on Disappointing Earnings
Roth Capital Analysts Give Cherokee  a $2.00 Price Target
Roth Capital Analysts Give Cherokee a $2.00 Price Target


© 2006-2018 Ticker Report. Google+.